In vitro and in vivo percutaneous absorption of retinol from cosmetic formulations: Significance of the skin reservoir and prediction of systemic absorption

Toxicology and Applied Pharmacology

Volumn 231, Issue 1, 2008, Pages 117-121

  Yourick, Jeffrey J ^a   Jung, Connie T ^a   Bronaugh, Robert L ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

Absorption; Dermal; Lipophilic; Retinol; Skin

Indexed keywords

COSMETIC; HYDROALCOHOLIC GEL; RECEPTOR FLUID; RETINOL; WATER OIL CREAM;

ANIMAL TISSUE; ARTICLE; DIAGNOSTIC ACCURACY; DIFFUSION; DOSE TIME EFFECT RELATION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG FECES LEVEL; DRUG FORMULATION; DRUG TISSUE LEVEL; DRUG URINE LEVEL; FEMALE; FUZZY RAT; GEL; HUMAN; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; LIPOPHILICITY; NONHUMAN; PREDICTION; RAT; SKIN ABSORPTION; SKIN RECEPTOR; SYSTEMIC CIRCULATION; TISSUE PRESERVATION;

ANIMALS; CHEMISTRY, PHARMACEUTICAL; COSMETICS; EMULSIONS; FEMALE; GELS; RATS; SKIN ABSORPTION; VITAMIN A;

RATTUS;

EID: 48449102474     PISSN: 0041008X     EISSN: 10960333     Source Type: Journal    
DOI: 10.1016/j.taap.2008.04.006     Document Type: Article

References (32)

1. Anonymous. Teratology Society position paper: recommendations for vitamin A use during pregnancy. Teratology 35 (1987) 269-275
2. Anonymous. Exposure Factors Handbook (1997), U. S. Environmental Protection Agency, Washington, D.C.
3. Anonymous. Merck Index. Thirteenth Ed. (2001), p, Merck and Co 10074
4. Anonymous. OECD Guideline for the Testing of Chemicals: Skin Absorption (in vitro method) (2004), Organization for Economic Cooperation and Development, Paris
5. Anonymous. Basic Criteria for the in vitro Assessment of Dermal Absorption of Cosmetic Ingredients, Updated March 2006 (2006), Scientific Committee on Consumer Products, European Commission
6. Bailly J., Crettaz M., Schifflers M.H., and Marty J.P. In vitro metabolism by human skin and fibroblasts of retinol, retinal and retinoic acid. Exp. Dermatol. 7 (1998) 27-34
7. Baumann L., Vujevich J., Halern M., Martin L.K., Kerdel F., Lazarus M., Pacheco H., Black L., and Bryde J. Open-label pilot study of alitretinoin gel 0.1% in the treatment of photoaging. Cutis 76 (2005) 69-73
8. Boehnlein J., Sakr A., Lichtin J.L., and Bronaugh R.L. Characterization of esterase and alcohol dehydrogenase activity in skin. Metabolism of retinyl palmitate to retinol (vitamin A) during percutaneous absorption. Pharm. Res. 11 (1994) 1155-1159
9. Bronaugh R.L., and Stewart R.F. Methods for in vitro percutaneous absorption studies. III. Hydrophobic compounds. J. Pharm. Sci. 73 (1984) 1255-1258
10. Bronaugh R.L., and Collier S.W. Protocol for in vitro percutaneous absorption studies. In: Bronaugh R.L., and Maibach H.I. (Eds). In vitro Percutaneous Absorption: Principles, Fundamentals, and Application (1991), Boca Raton, CRC Press 237-241
11. Bronaugh R.L., Stewart R.F., and Simon M. Methods for in vitro percutaneous absorption studies. VII: use of excised human skin. J. Pharm. Sci. 75 (1986) 1094-1097
12. CERHR (Center for the Evaluation of Risks to Human Reproduction). Vitamin A (2005). http://cerhr.niehs..gov/common/vitaminA.html http://cerhr.niehs..gov/common/vitaminA.html
13. Collier S.W., Sheikh N.M., Sakr A., Lichtin J.L., Stewart R.F., and Bronaugh R.L. Maintenance of skin viability during in vitro percutaneous absorption/metabolism studies. Toxicol. Appl. Pharmacol. 99 (1989) 522-533
14. Collins M.D., Eckhoff C., Bochert G., and Nau H. 4-Methylpyrazole partially ameliorated the teratogenicity of retinol and reduced the metabolic formation of all-trans-retinoic acid in the mouse. Arch. Toxicol. 66 (1992) 652-659
15. ECETOC (European Centre for Ecotoxicology and Toxicology of Chemicals). Technical Report No. 58, Assessment of Non-Occupational Exposure to Chemicals, Brussels (1994) 20
16. FDA. FDA Talk Paper: Vitamin A and Birth Defects (1995). http://www.fda.gov/bbs/topics/ANSWERS/ANS00689.html http://www.fda.gov/bbs/topics/ANSWERS/ANS00689.html
17. FDA, 1998. Draft guidance for industry, topical dermatological drug product NDAs and ANDAs - in vivo bioavailability, bioequivalence, in vitro release, and associated studies, USHHS, FDA, CDER.
18. Franz T.J., and Lehman M.S. Systemic absorption of retinoic acid. J. Toxicol.-Cut. Ocular Toxicol. 8 (1990) 517-524
19. Geelan J.A. Hypervitaminosis A induced teratogenesis. CRC Crit. Rev. Toxicol. 6 (1979) 351-375
20. Gilchrest B.A. Treatment of photodamage with topical tretinoin: an overview. J. Amer. Acad. Dermatol. 36 (1997) S27-S36
21. Hathcock J.N., Hattan D.G., Jenkens M.Y., McDonald J.T., Sundaresan P.R., and Wilkening V.L. Evaluation of vitamin A toxicity. Am. J. Clin. Nutr. 52 (1990) 183-202
22. Hood H.L., Wickett R.R., and Bronaugh R.L. The in vitro percutaneous absorption of the fragrance ingredient musk xylol. Food Chem. Toxicol. 34 (1996) 483-488
23. Kang S., Duell E.A., Fisher G.J., Datta S.C., Wang Z.-Q., Reddy A.P., Tavakkol A., Yi J.Y., Griffiths C.E.M., Elder J.T., and Vorhees J.J. Application of retinol to human skin in vivo induces epidermal hyperplasia and cellular retinoid binding proteins characteristic of retinoic acid but without measurable retinoic acid levels or irritation. J. Invest. Dermatol. 105 (1995) 549-556
24. Kang S., Leyden J.J., Lowe N.J., Ortonne J.-P., Phillips T.J., Weinstein G.D., Bhawah J., Lew-Kaya D.A., Matsunoto R.M., Sefton J., Walker P.S., and Gibson J.R. Tazarotene cream for the treatment of facial photodamage: a multicenter, investigator-masked, randomized, vehicle-controlled, parallel comparison of 0.01%, 0.025%, 0.05% and 0.1% tazarotene creams with 0.05% tretinoin emollient cream applied once daily for 24 weeks. Arch. Dermatol. 137 (2001) 1597-1604
25. Kraeling M.E.K., and Bronaugh R.L. In vitro percutaneous absorption of alpha hydroxy acids in human skin. J. Soc. Cosmet. Chem. 48 (1997) 187-197
26. Kraeling M.E.K., Yourick J.J., and Bronaugh R.L. In vitro human skin penetration of diethanolamine. Food Chem. Toxicol. 42 (2004) 1553-1561
27. Lauer A.C., Elder J.T., and Weiner N.D. Evaluation of the hairless rat as a model for in vivo percutaneous absorption. J. Pharm. Sci. 86 (1997) 13-18
28. Marill J., Idres J., Capron C., Nguyen E., and Chabot G. Retinoic acid metabolism and mechanism of action. Curr. Drug Metab. 4 (2003) 1-10
29. Wester R.C., and Maibach H.I. Regional variation in percutaneous absorption: principles and applications to human risk assessment. In: Bronaugh R.L., and Maibach H.I. (Eds). Percutaneous Absorption. 4th Edition (2005), Taylor & Francis, New York 85-106.
30. Yan J., Wamer W.G., Howard P.C., Boudreau M.D., and Fu P.P. Levels of retinyl palmitate and retinol in the stratum corneum, epidermis, and dermis of female SKH-1 mice topically treated with retinyl palmitate. Toxicol. Ind. Health 22 (2006) 181-191
31. Yourick J.J., Koenig M.L., Yourick D.L., and Bronaugh R.L. Fate of chemicals in skin after dermal application: does the in vitro skin reservoir affect the estimate of systemic absorption?. Toxicol. Appl. Pharmacol. 195 (2004) 309-320
32. Zhai H., Dreher F., Maibach H.I., Choi M.J., and Loffler H. Effect of tape stripping on percutaneous penetration and topical vaccination. In: Bronaugh R.L., and Maibach H.I. (Eds). Percutaneous Absorption. 4th Edition (2005), Taylor & Francis, New York 811-821